298 completed, 62 unknown, 26 terminated, 26 withdrawn. 439 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 439 | Completed 298, Unknown 62, Terminated 26, Withdrawn 26, Recruiting 14, Not yet recruiting 9, Active not recruiting 4 |
Follow Pulmonary Disease, Chronic Obstructive: new trials by email Literature Review of Pulmonary Disease, Chronic Obstructive trials Research Report on Pulmonary Disease, Chronic Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RSV Vaccination to Reduce Recurrent AECOPD RSV vaccination (Arexvy, GlaxoSmithKline) - COPD, RSV | Phase 4 | Not yet recruiting | Chinese University of Hong Kong | 320 | 2027-07-01 | 2026-04-13 |
| Comparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype Roflumilast Oral Tablet, Azithromycin 250 mg - Chronic Obstructive Pulmonary Disease With Exacerbation | Phase 4 | Not yet recruiting | Sidra Aziz | 70 | 2027-02-01 | 2026-08-31 |
| Effect of add-on Doxofylline on Lung Function in Stable COPD Doxofylline - Chronic Obstructive Pulmonary Disease | Phase 4 | Not yet recruiting | University of Milan | 78 | 2026-12-01 | 2026-04-29 |
| This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization dupilumab, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 754 | 2026-10-06 | 2026-10-16 |
| Airway Dysfunction, Occlusions and Remodeling: COPD Patients and Mepolizumab Mepolizumab 100 MG Injection - COPD (Chronic Obstructive Pulmonary Disease) | Phase 4 | Not yet recruiting | Western University, Canada | 36 | 2026-10-01 | 2026-08-06 |
| Study to Evaluate the Effects of Oral Glyceryl Guiacolate (Guaifenesin, GGE) on Sputum Rheology in Subjects With Mucus Hypersecretion Glycerol Guiacolate, SOC (Standard of care) - Bronchitis, Bronchitis, Chronic | Phase 4 | Not yet recruiting | University of North Carolina, Chapel Hill | 40 | 2026-10-01 | 2026-10-14 |
| Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD Nebulized therapy of similar medication solutions, Continue handheld therapy - COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Recruiting | COPD Foundation | 120 | 2026-07-14 | 2026-09-14 |
| 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg - Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Recruiting | Western University, Canada | 60 | 2026-04-24 | 2026-07-31 |
| Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) Methylprednisolone (drug), Hydrocortisone - Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Recruiting | Copenhagen Respiratory Research | 2000 | 2026-03-10 | 2026-03-18 |
| Effect of Noninvasive Ventilation on Physical Activity and Inflammation in COPD Patients Control, NIMV group - Chronic Obstructive Pulmonary Disease, Hypercapnic | Phase 4 | Unknown | Hospital Universitario La Paz | 50 | 2025-12-01 | 2023-03-06 |
| A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation Budesonide/Glycopyrronium/Formoterol Fumarate, Placebo, Metered dose inhaler - Chronic Obstructive Pulmonary Disease, Hyperinflation | Phase 4 | Recruiting | AstraZeneca | 56 | 2025-11-24 | 2026-09-18 |
| A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. Dupilumab, Placebo - Chronic Obstructive Pulmonary Disease | Phase 4 | Recruiting | Sanofi | 218 | 2025-09-22 | 2026-10-20 |
| Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency 20-valent pneumococcal conjugate vaccine - Alpha 1-Antitrypsin, COPD | Phase 4 | Recruiting | University of Alabama at Birmingham | 30 | 2025-09-03 | 2026-10-27 |
| Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotics and Steroids? biomarker-guided decision making, GOLD recommendations - Chronic Obstructive Pulmonary Disease, COPD | Phase 4 | Not yet recruiting | Ottawa Hospital Research Institute | 80 | 2025-09-01 | 2025-04-16 |
| Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules Bailing Capsules in combination Guben Kechuan Granules - Bronchiectasis, COPD | Phase 4 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 214 | 2025-07-14 | 2025-08-11 |
| Effects of CreaSafe® on Kidney, Muscle, and Cardiopulmonary Function in Athletes and COPD Patients CreaSafe® creatine, Placebo 0.03 g/kg/day - Copd, Athletes | Phase 4 | Not yet recruiting | Federal University of São Paulo | 140 | 2025-07-01 | 2025-05-28 |
| Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease Titrated Oxygen, Standard Oxygen - COPD Exacerbation, COPD Exacerbation Acute | Phase 4 | Recruiting | Central Denmark Region | 1888 | 2025-06-02 | 2026-10-02 |
| Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study Budesonide/Glycopyrronium/Formoterol (BGF), Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) - COPD, Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Completed | Thammasat University | 22 | 2025-04-01 | 2026-02-02 |
| Air Pollution and Inhaled Corticosteroids in COPD LABA+LAMA, LABA+LAMA+ICS, Filtered Air - COPD | Phase 4 | Not yet recruiting | University of British Columbia | 48 | 2025-04-01 | 2025-03-27 |
| A Randomized, Safety and Efficacy Study of Taneasy 600mg Granules and Fluimucil 600mg Granules in COPD Subjects Taneasy 600mg granules, Fluimucil 600mg granules - COPD (Chronic Obstructive Pulmonary Disease) | Phase 4 | Completed | Bun Yao Biotechnology Co., Ltd | 45 | 2025-02-20 | 2025-09-18 |
Showing 20 of 439. Sign in to see all of them.
Bronchitis, Chronic (33) · Emphysema (30) · Asthma (24) · Motor Activity (19) · Dyspnea (15) · Bronchitis (13) · Lung Diseases (12) · Lung Diseases, Obstructive (12) · Pneumonia (8) · Inflammation (7) · Respiratory Aspiration (6) · Respiratory Insufficiency (6) · Heart Failure (5) · Smoking (5)
Chronic Disease (439) · Disease Attributes (439) · Pathologic Processes (439) · Pathological Conditions, Signs and Symptoms (439) · Respiratory Tract Diseases (435) · Lung Diseases (427) · Lung Diseases, Obstructive (427) · Bronchial Diseases (70) · Infections (58) · Respiratory Tract Infections (50) · Behavior (33) · Bronchitis (32) · Respiration Disorders (29) · Immune System Diseases (27) · Hypersensitivity (25)
Tiotropium Bromide (67) · Formoterol Fumarate (40) · Salmeterol Xinafoate (37) · Fluticasone (33) · Budesonide (28) · indacaterol (22) · Albuterol (20) · Glycopyrrolate (17) · Budesonide, Formoterol Fumarate Drug Combination (14) · Fluticasone-Salmeterol Drug Combination (12) · Ipratropium (12) · aclidinium bromide (10) · Roflumilast (9) · Acetazolamide (8) · Acetylcysteine (8)
GlaxoSmithKline (38) · Boehringer Ingelheim (32) · Novartis Pharmaceuticals (24) · AstraZeneca (18) · University of Zurich (13) · University of Milan (8) · Queen's University (7) · University of Dundee (7) · Neutec Ar-Ge San ve Tic A.Ş (6) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (5) · National Institute of Respiratory Diseases, Mexico (5) · Sanofi (5) · Chronic Obstructive Pulmonary Disease Trial Network, Denmark (4) · Federal University of São Paulo (4) · Imperial College London (4)
United States (102) · Germany (51) · United Kingdom (49) · Canada (43) · Spain (41) · Netherlands (34) · Denmark (33) · Italy (33) · China (31) · Belgium (23) · France (20) · Brazil (16) · Sweden (15) · Austria (14) · Russia (14)
Konrad E Bloch, MD (11) · Talant M Sooronbaev, MD (10) · Denis E O'Donnell, MD (3) · Pierachille Santus, MD, PhD (3) · Silvia Ulrich, MD (3) · Tomas Andersson, MD (3) · Denis E O'Donnell, MD, FRCPC (2) · Grace Parraga, PhD (2) · Hanqing He (2)
PMID 11019457, PMID 16322646, PMID 16799080, PMID 17310045, PMID 17951621, PMID 18625750, PMID 18804362, PMID 19897551, PMID 21428765, PMID 23613569, PMID 29763572, PMID 39756820, PMID 8810608, PMID 10430726, PMID 11377644, PMID 11401887, PMID 11491153, PMID 11549531, PMID 12114338, PMID 12204862, PMID 12570114, PMID 15229100, PMID 15539711, PMID 15591470, PMID 15764761, PMID 15955146, PMID 16055868, PMID 16055882, PMID 16113473, PMID 16135736, PMID 16144890, PMID 16157462, PMID 16203030, PMID 16235327, PMID 16310554, PMID 16396956, PMID 16844726, PMID 16899830, PMID 16914336, PMID 17088091, PMID 17532532, PMID 17605774, PMID 17646228, PMID 17678942, PMID 17765528, PMID 17951276, PMID 18039368, PMID 18162137, PMID 18310480, PMID 18403672
2017 (12), 2015 (5), 2019 (5), 2014 (4), 2016 (4), 2025 (3), 2008 (2), 2018 (2), 2023 (2), 2009 (1), P50HL084945 (1), R01HL080414 (1), R01HL133240 (1), R01HL139365 (1)